These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37342592)

  • 1. Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches.
    Zhang Y; Xie P; Li Y; Chen Z; Shi A
    Front Pharmacol; 2023; 14():1142003. PubMed ID: 37342592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
    Mori K; Saito R; Nakamaru Y; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2016 Nov; 37(8):491-506. PubMed ID: 27604638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes.
    Derosa G; Maffioli P
    Ther Clin Risk Manag; 2018; 14():1637-1640. PubMed ID: 30237717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
    Yamaguchi K; Kato M; Suzuki M; Hagita H; Takada M; Ayabe M; Aso Y; Ishigai M; Ikeda S
    J Pharmacol Exp Ther; 2013 Apr; 345(1):52-61. PubMed ID: 23386251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
    Patel K; Carbone A
    Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.
    Demin O; Yakovleva T; Kolobkov D; Demin O
    Front Pharmacol; 2014; 5():218. PubMed ID: 25352807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY; Liu SY; Yin DG
    Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
    Que L; Huang K; Xiang X; Ding Y; Chu N; He Q
    J Clin Pharm Ther; 2022 Aug; 47(8):1225-1231. PubMed ID: 35362180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
    Posch MG; Walther N; Ferrannini E; Powell DR; Banks P; Wason S; Dahmen R
    Diabetes Care; 2022 Sep; 45(9):2118-2126. PubMed ID: 35817022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans.
    Kim MS; Song YK; Choi JS; Ji HY; Yang E; Park JS; Kim HS; Kim MJ; Cho IK; Chung SJ; Chae YJ; Lee KR
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms.
    Semo D; Obergassel J; Dorenkamp M; Hemling P; Strutz J; Hiden U; Müller N; Müller UA; Zulfikar SA; Godfrey R; Waltenberger J
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose Cotransporter 2 Inhibitors' Rise to the Backbone of Heart Failure Management: A Clinical Review.
    Rohant N; Kennedy JL
    Heart Int; 2021; 15(1):42-48. PubMed ID: 36277321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats.
    Yamaguchi K; Kato M; Suzuki M; Asanuma K; Aso Y; Ikeda S; Ishigai M
    Drug Metab Dispos; 2011 Oct; 39(10):1801-7. PubMed ID: 21712434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
    Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.
    Lukic N; Macvanin MT; Gluvic Z; Rizzo M; Radak D; Suri JS; Isenovic ER
    Curr Med Chem; 2024; 31(30):4781-4806. PubMed ID: 37855338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
    Cefalo CMA; Cinti F; Moffa S; Impronta F; Sorice GP; Mezza T; Pontecorvi A; Giaccari A
    Cardiovasc Diabetol; 2019 Feb; 18(1):20. PubMed ID: 30819210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
    Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
    Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.